Stockreport

ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer [Yahoo! Finance]

ALX Oncology Holdings Inc.  (ALXO) 
PDF As of December 31, 2023, cash equivalents and investments were $218.1 million. The company says the cash balance and the ability to draw down an additional $40 millio [Read more]